Center of Medicine

REVIEW ARTICLE

Nonalcoholic fatty liver disease (NAFLD): Pathological mechanisms, risk factors, and modern therapeutic challenges

Karrar Ali Hussein Al-Ghazzawi*[1], Asmaa Abdeltwab Mahmoud[2], Douaa saadi salim[3], Safa M. Salim[4], Zainab Muzahim Mohammed[5]

[1] University of Warith al-Anbiyaa, Iraq.

[2] Alexandria University, Care department Alexandria Faculty of Medicine, Egypt.

[3] University of Basrah, Al Zahraa college of medicine, Iraq.

[4] Northern Technical University, Department of Cancer Research and Hereditary Blood Diseases,Technical Research Center, Iraq.

[5] University of Basrah, Al Zahraa college of medicine, Department of biochemistry, Iraq.

*Corresponding author E-mail: karrar.ali@uowa.edu.iq

Article Info.

Article history:

Received: 13/01/2026

Accepted: 25/01/2026

Published: 25/01/2026

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide. It is characterized by the accumulation of fat within liver cells, which can negatively impact liver function. This disease is often silent in its early stages, with no apparent symptoms. However, as the condition progresses, symptoms of fatty liver disease may begin to appear, posing an increasing health challenge due to its close association with obesity, type 2 diabetes, and metabolic syndrome. This research aims to review current understandings of the pathogenesis of NAFLD, analyze the risk factors contributing to its development, and discuss current treatment challenges and future research directions. The study employs a theoretical and analytical research methodology, reviewing recent medical literature and highlighting research gaps in this area.

Keywords: Non-alcoholic fatty liver disease, liver disease, obesity, cirrhosis.

Introduction

Recent decades have witnessed a significant increase in the incidence of chronic liver diseases, with non-alcoholic fatty liver disease (NAFLD) being among the most prevalent. This disease is defined as the accumulation of fat in liver cells exceeding 5% without excessive alcohol consumption or other secondary causes [1]. Its danger lies in its potential progression to fatty liver disease, then cirrhosis, and possibly primary liver cancer [2]. Therefore, the importance of studying this disease from a comprehensive scientific perspective that integrates pathophysiological mechanisms and therapeutic challenges is paramount. Fatty liver disease may not present obvious symptoms in its early stages but can lead to hepatitis and liver damage over time [3]. Treatment includes dietary modifications, exercise, and weight loss to prevent complications and improve liver health. Drug therapy primarily aims to improve liver disease and is generally limited to those with a biopsy confirming non-alcoholic fibrosis and cirrhosis.

2. Research Problem

Despite the widespread prevalence of non-alcoholic fatty liver disease (NAFLD), the disease is still often diagnosed at late stages, and effective drug treatment options remain limited [4]. The research problem lies in the need for a deeper understanding of the pathogenesis and risk factors influencing disease progression, which will contribute to improving prevention and treatment strategies.

3. Significance of the Research

The significance of this research stems from several key points, which we summarize below:

3.1 The global rise in the prevalence of the disease.

3.2 Its close association with common chronic diseases.

3.3 The limited availability of currently approved drug treatments.

3.4 The need to direct future research towards effective treatment strategies.

4. Research Objectives

The research aims to achieve a set of results or objectives, which can be summarized as follows:

4.1 To clarify the scientific concept of non-alcoholic fatty liver disease.

4.2 To analyze the pathological mechanisms causing the disease.

4.3 To identify the risk factors associated with its development.

4.4 To discuss current treatment challenges.

4.5 To review future research directions.

5. Research Methodology

The research adopted a theoretical and analytical approach through reviewing and analyzing studies and research published in peer-reviewed medical journals, with a focus on recent literature related to fatty liver disease.

6. Previous Studies

Importance of Non-Alcoholic Fatty Liver Disease (NASH): This is the inflammatory form of non-alcoholic fatty liver disease (NAFLD) and is associated with disease progression, the development of cirrhosis, and the need for liver transplantation. Despite its importance, the diagnosis of NASH is not given sufficient attention in clinical practice.

Study [5] Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) is estimated to affect 3% to 6% of the US population, and its prevalence is increasing. It is closely associated with obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome. Although several non-invasive tests and assessment systems exist for the diagnosis of NAFLD and NASH, liver biopsy is the only proven diagnostic method for NASH. Currently, there are no FDA-approved treatments specifically for NASH. Lifestyle modification is the cornerstone of treatment, including dietary changes and exercise, with weight loss being the primary goal. Significant improvement in histological findings, including fibrosis, is directly related to increased weight loss. In some cases, bariatric surgery may be necessary to achieve and maintain the degree of weight loss required for therapeutic effect. Approximately 20% of patients with NASH are expected to develop cirrhosis, and NASH is projected to become the leading cause of liver transplantation in the United States. The mortality rate among patients with NASH is significantly higher than in the general population or those without this inflammatory form of NASH, with an annual all-cause mortality rate of 25.56 per 1,000 person-years and a liver-specific mortality rate of 11.77 per 1,000 person-years. NASH affects 3% to 6% of the US population, is more common in patients with metabolic disorders and obesity, progresses to cirrhosis in approximately 20% of cases, and is associated with high liver-related mortality and overall mortality. Early diagnosis and targeted treatment of NASH are essential for improving treatment outcomes, including intensive lifestyle modifications to promote weight loss and referral to bariatric surgery when needed.

Study [6] Effects of Diet and Lifestyle on Insulin Resistance in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review

Nonalcoholic fatty liver disease (NAFLD) results from excessive fat accumulation in the liver without excessive alcohol consumption. Insulin resistance (IR) is believed to be an underlying pathogen in the development and progression of the disease. Currently, there are no proven drug therapies, and weight loss is the only prescribed treatment, although there is no evidence to support specific diets or lifestyle modifications. This review aimed to evaluate the effectiveness of dietary and lifestyle-related interventions on insulin resistance, as measured by the Homeostasis Assessment Model-1 (HOMA-1), in patients with NAFLD. Two independent reviewers conducted a systematic electronic search of the Medline, Scopus, Cochrane Library, CINAHL, and PubMed databases (1999–2015). The review included randomized

controlled trials evaluating the effectiveness of dietary and lifestyle interventions on insulin resistance in adults diagnosed with non-alcoholic fatty liver disease (NAFLD). A total of 6,441 articles were identified, including eight randomized controlled trials that met the inclusion criteria. Three studies included dietary interventions, while five combined diet and exercise. The majority of intervention groups resulted in significant reductions in insulin resistance, while no significant changes were observed in the control groups. Lifestyle interventions, compared to the control groups, contributed to a reduction in insulin resistance as assessed by the homeostasis model. All dietary intervention trials, whether combining diet and lifestyle, were effective in reducing insulin resistance in participants with NAFLD. Given the limited number of published studies and the variability in interventions, further research is needed to develop specific dietary and lifestyle recommendations.

Study [7] Lifestyle Modifications for Non-Alcoholic Fatty Liver Disease: A Network Meta-analysis

The evidence suggests considerable uncertainty regarding the effects of lifestyle interventions compared to no additional intervention (besides general health advice) on any clinical outcomes after a short follow-up period of 2 to 24 months in individuals with non-alcoholic fatty liver disease. Therefore, high-quality randomized clinical trials with adequate follow-up are needed. We propose either a randomized, registry-based clinical trial or a multi-group randomized clinical trial (a study design in which multiple interventions are tested in large longitudinal groups of participants to achieve efficiency and more closely align trials with standard clinical practice) to compare aerobic exercise and dietary advice versus standard care (exercise and dietary advice provided as part of national health promotion programs). The rationale for choosing aerobic exercise and dietary advice is the impact of these interventions on indirect outcomes that may translate into clinical benefit. The results of these trials should include mortality rates, health-related quality of life, decompensated cirrhosis, liver transplantation, and measures of resource utilization, including intervention costs and reduced healthcare utilization after at least eight years of follow-up, in order to find clinically significant differences in outcomes.

7. Theoretical Framework: The Concept of Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is classified as a metabolic liver disease, encompassing a spectrum of conditions that begins with simple fatty liver and may progress to active inflammation and cirrhosis. Studies indicate that impaired lipid metabolism and insulin resistance play a pivotal role in the development of the disease. NAFLD is described as a common condition in which fat accumulates in the liver, often associated with weight gain, and is usually treatable with healthy lifestyle changes. Therefore, it is also called metabolic-associated fatty liver disease (MASLD). It is also a type of fatty liver disease where fat is deposited in the liver (steatohepatitis) due to alcohol use. It is a common disease in developing countries [8]. Non-alcoholic fatty liver disease (NAFLD) requires a treatment protocol, regardless of whether the affected person is overweight or not. This disease is a major cause of preventable death [9]. The following image accurately depicts the condition of non-alcoholic fatty liver disease in humans, as the microscopic images show a high percentage of non-alcoholic fatty liver disease, which takes on a white, altered color according to the trichrome image



Fig. 1: Microscopic image of non-alcoholic fatty liver disease [10].

8. Pathophysiological mechanisms, as described in the scientific research of Parker HM et al. (2012:55) [11] , include:

8.1 Insulin resistance, leading to increased free fatty acid influx into the liver.

8.2 Oxidative stress resulting from fat accumulation.

8.3 Chronic inflammation and activation of hepatic stellate cells.

8.4 Intestinal microbiome imbalance during inflammation and its impact on the gut-hepatocyte axis.



Fig. 2: Illustrates the stages of non-alcoholic fatty liver disease.

The first stage (fatty degeneration) involves fat accumulation, but no liver damage occurs at this stage. In the second stage (non-alcoholic steatohepatitis - NASH), the fat accumulation causes inflammation of the liver, but the liver is not yet seriously damaged. However, there is a risk of the condition worsening in the future. When the inflammation or damage progresses to another stage, signs of liver damage appear, but the liver usually continues to function well. However, it is essential to try to prevent further damage that could lead to cirrhosis. If the condition continues to worsen and progresses to a more serious stage, it causes severe liver damage that impairs its function and can lead to serious health problems, including internal bleeding, liver failure, liver cancer, or sepsis. Academic and medical statistics show that 1-2% of patients with NASH develop cirrhosis annually. Cirrhosis is the final stage of the disease, and anyone who develops it will eventually experience liver failure and require a transplant. Liver, as shown in the following picture:



Fig. 3: represents the stages of liver damage and failure pictorially.

9. Risk Factors

The main risk factors for non-alcoholic fatty liver disease (NAFLD) include obesity, especially abdominal obesity, type 2 diabetes, and high cholesterol. Genetic predisposition also plays a role, as does a sedentary lifestyle.

10. Treatment Challenges

The treatment challenges for NAFLD include the lack of a definitively proven drug therapy with conclusive results, the need for significant lifestyle modifications, and the difficulty patients face in adhering to the long-term behavioral changes required for prevention and treatment. Furthermore, there is a need for treatments that target the various underlying pathological mechanisms.



Fig. 4: Healthy liver vs. Fatty liver disease.

11. Conclusions

Nonalcoholic fatty liver disease (NAFLD) is a complex, multifactorial disease with varying stages of progression and severity. This necessitates a comprehensive treatment approach that combines prevention, early diagnosis, and integrated therapy to maintain individual health and reduce the incidence of worsening cases. The research emphasizes the need to intensify scientific research efforts to find effective treatment solutions that can be adopted for future treatment protocols for patients.

12. Recommendations

12.1 Strengthen health awareness programs and focus on the risks of inflammation worsening if the disease stages are ignored.

12.2 Support advanced scientific and clinical research on diverse patient models of NAFLD to achieve accurate diagnosis and develop successful treatment solutions.

12.3 Direct health authorities to develop plans for periodic community-based protocols for early diagnosis when a certain incidence is identified, determining the stage of inflammation, and preventing future progression of the condition.

12.4 Working to raise awareness in human society about the need to adopt and encourage a healthy lifestyle and life path for individuals.

13. Future Research Trends and Suggestions Related to the Research Paper Title

Recent research focuses on a range of important scientific topics and themes. We suggest the following:

13.1 Targeted therapies for inflammatory pathways and lipid metabolism modifiers.

13.2 The role of probiotics and the gut microbiome.

13.3 Genetically based personalized medicine.

References:

[1] J.-S. Kang, H.-J. Kim, S.-J. Lim, S.-W. Lee, and I. Hwang, "An Overview of Nonalcoholic Fatty Liver Diseases (NAFLD)," 2025.

[2] M.-P. Li and K.-Z. Luo, "The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease," Hepatobiliary & Pancreatic Diseases International, 2025.

[3] M. Fazan, G. Selvi, and A. Krishnan, "Liver Cirrhosis and Its Management: A Comprehensive Review on Etiology, Complications, Emerging Hepatoprotective Agents and Novel Treatment Modalities," International Journal of Scientific Research and Technology, 2025.

[4] A. Kozłowska, "Clinical Insights into Non-Alcoholic Fatty Liver Disease and the Therapeutic Potential of Flavonoids: An Update," Nutrients, vol. 17, no. 6, p. 956, 2025.

[5] D. A. Koutoukidis et al., "Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis," JAMA internal medicine, vol. 179, no. 9, pp. 1262-1271, 2019.

[6] T. Paris, E. S. George, S. K. Roberts, and A. C. Tierney, "The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review," European journal of gastroenterology & hepatology, vol. 29, no. 8, pp. 867-878, 2017.

[7] M. Romero-Gómez, S. Zelber-Sagi, and M. Trenell, "Treatment of NAFLD with diet, physical activity and exercise," Journal of hepatology, vol. 67, no. 4, pp. 829-846, 2017.

[8] V. W. S. Wong et al., "Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—part 1: definition, risk factors and assessment," Journal of gastroenterology and hepatology, vol. 33, no. 1, pp. 70-85, 2018.

[9] N. Chalasani et al., "The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases," Hepatology, vol. 67, no. 1, pp. 328-357, 2018.

[10] S. Chitturi et al., "The Asia–Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017—part 2: management and special groups," Journal of gastroenterology and hepatology, vol. 33, no. 1, pp. 86-98, 2018.

[11] H. M. Parker, N. A. Johnson, C. A. Burdon, J. S. Cohn, H. T. O'Connor, and J. George, "Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis," Journal of hepatology, vol. 56, no. 4, pp. 944-951, 2012.